EZH2 also showed surprising results in reversing the chemotherapy resistance of cervical cancer cells (Cai et al., 2016), cisplatin resistance in epithelial ovarian cancer (Liu et al., 2014), melanoma resistance to immunotherapy (Emran et al., 2019), and resistance of prostate cancer (Shankar et al., 2020), and it can be described as the gospel for patients. The gene discussed is EZH2; the disease is prostate cancer.